Enveric Biosciences reports Q1 net loss of $2.46M, advances EB-003, signs seven non-binding term sheets

Enveric Biosciences, Inc.

2024-Q1 EPS reported -$0.61 vs consensus -$142.29 ▲ beat (+99.6%)

Net loss $2.46M ($0.61 per diluted share) vs $4.80M ($2.31) in Q1 2023; cash $6.36M.
Seven non-binding term sheets with four partners could yield up to $410M milestones plus future royalties.
Lead asset EB-003 advancing toward IND filing and Phase 1 trial.
Raised $4.5M from warrant exercises in Q1.
Drug discovery platform generated >1,000 proprietary candidates across seven molecule classes.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Enveric Biosciences, Inc. reported the first quarter ended March 31, 2024 results: net income $2.46 million, EPS $0.61.

Period: the first quarter ended March 31, 2024
Net income: $2.46 million
EPS: $0.61
Result: reported results

Exact text from the filing

Enveric Biosciences, Inc. issued a press release providing a corporate update and announcing its financial results for the first quarter ended March 31, 2024.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Enveric Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-019362

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.